benzyl α-bromo-o-toluate | 115975-28-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl α-bromo-o-toluate
• 英文别名: Benzyl 2-(bromomethyl)benzoate
• CAS: 115975-28-5
• 化学式: C₁₅H₁₃BrO₂
• 分子量: 305.171
• InChiKey: REPPXUCYHRQWKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  benzyl α-bromo-o-toluate 、 苯 以74%的产率得到
  参考文献：
  名称：

  FUKUOKA, SATOSHI;NANRI, HIROSHI;KATSUKI, TSUTOMU;YAMAGUCHI, MASARU, TETRAHEDRON LETT., 28,(1987) N 49, 6205-6206

  摘要：

  DOI：

文献信息

• Activation of carboxylic acids and alcohols by intramolecular cyclization. Acylation of trimethylsilyacetylenes and alkylation of aromatic compounds.
  作者：Satoshi Fukuoka、Hiroshio Nanri、Tsutomu Katsuki、Masaru Yamaguchi

  DOI：10.1016/s0040-4039(00)61847-6

  日期：1987.1

  Carboxylic α-bromo--toluic anhydrides and alkyl α-bromo--toluates were activated by silver salts and used for the acylation of trimethylsilylacetylenes to acetylenic ketones and alkylation of aromatic compounds, respectively.

  羧基α-溴-甲苯酸酐和烷基α-溴-甲苯酸酯被银盐活化，分别用于将三甲基甲硅烷基乙炔酰化为乙炔酮和将芳族化合物烷基化。
• [EN] CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS<br/>[FR] ACIDES HYDROXAMIQUES CYCLIQUES UTILISES EN TANT QU'INHIBITEURS DE METALLOPROTEASES
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1999065867A1

  公开（公告）日：1999-12-23

  (EN) The present application describes novel cyclic hydroxamic acids of formula (I): or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.(FR) La présente invention se rapporte à de nouveaux acides hydroxamiques cycliques représentés par la formule (I) ou à des sels pharmaceutiquement acceptables de ces acides. Dans la formule (I), le noyau B est un système cyclique comportant 5 à 7 éléments possédant 0 à 2 hétéroatomes sélectionnés parmi O, N, NRa, et S(O)p, et 0 à 1 groupe carbonyle, et les autres variables sont définies dans la description associée à la présente invention. Ces acides s'avèrent utiles en tant qu'inhibiteurs de métalloprotéases.

  本申请描述了新型的环状羟肟酸式化合物(I)或其药学上可接受的盐形式，其中环B是一个包含0-2个来自O、N、NRa和S(O)p的杂原子和0-1个羰基的5-7元环系统，其他变量在本说明书中定义，这些化合物可用作金属蛋白酶抑制剂。
• Novel Cyclic hydroxamic acid as metalloproteinase inhibitors
  申请人：——

  公开号：US20030139597A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR a , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.

  本申请描述了新型的环状羟肟酸，其化学式为I:1或其药用盐形式，其中环B为包含0-2个来自O、N、NRa和S(O)p的杂原子和0-1个羰基基团的5-7元环系统，而其他变量在本说明书中有定义，这些化合物可用作金属蛋白酶抑制剂。
• CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP1087937A1

  公开（公告）日：2001-04-04
• TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY
  申请人：Vrijbloed Jan Wim

  公开号：US20100056432A1

  公开（公告）日：2010-03-04

  Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depend on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa and Acinetobacter. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. In a specific embodiment, the template is based on the D-Pro-L-Pro dipeptides. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid—and solution phase synthetic strategy.